In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Hold rating on Pacira Pharmaceuticals (NASDAQ: PCRX), with a price target of $43. The company’s shares closed yesterday at $48.89, close to its 52-week high of $52.60.
Rivkind Koffler commented:
“We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating.”
According to TipRanks.com, Koffler is a 4-star analyst with an average return of 8.1% and a 43.1% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $51.62.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.60 and a one-year low of $26.95. Currently, Pacira Pharmaceuticals has an average volume of 573.3K.
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is neutral on the stock. Last month, David Stack, the CEO & Chairman of PCRX bought 45,000 shares for a total of $130,650.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Pharmaceuticals, Inc. is a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.
